Helicos BioSciences Joins Personalized Medicine Coalition

Helicos BioSciences Corporation has joined the Personalized Medicine Coalition (PMC), an educational and advocacy group dedicated to advancing the understanding and adoption of personalized medicine.

Helicos BioSciences is a life science company focused on innovative genetic analysis technologies for the research, drug discovery and diagnostic markets. Helicos’ proprietary tSMS™ technology allows direct measurement of billions of strands of DNA enabling scientists to perform experiments and ask questions never before possible. Helicos is a recipient of the $1,000 genome grant and is committed to providing scientists the tools to unlock the era of genomic medicine.

“We believe that Helicos’ technology will enable personalized medicine to become a reality and feel it’s crucial for us to have a strong public policy voice. Living in an era where patients will have the opportunity to have their genome sequenced, it’s essential for us to join the discussion on how society will deal with this scientific breakthrough,” said Patrice Milos, Ph.D., Helicos’ Vice President and Chief Scientific Officer.

“Having watched the PMC since its formation, I have admired the strong policy voice that the PMC has demonstrated. We at Helicos are eager to join its membership and work together to determine how personalized medicine can best be developed to make a difference in healthcare,” Dr. Milos added.

“We are honored to have Helicos BioSciences join our coalition to ensure that public opinion and policy are aligned with personalized medicine’s new and emerging scientific paradigms,” said Edward Abrahams, Executive Director of the PMC. “At a time when so many unprecedented social, political and financial challenges face health care today, it is especially important to have a forward-looking company like Helicos add its voice to help us make personalized medicine a reality.”